Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Novy Hradec Kralove – page 15

207 clinical trials in Novy Hradec Kralove, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Novy Hradec Kralove at a glance
207
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

207 trials in Novy Hradec Kralove

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Celgene Corp.

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Study on the Safety and Effects of STAR-0215 for Adults with Hereditary Angioedema

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:STAR-0215
  • Sponsor:Astria Therapeutics Inc.

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Diffuse large B-cell lymphoma refractory

Not recruiting

Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of RO7434656 for Patients with Primary IgA Nephropathy at High Risk of Progression

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 696844
  • Sponsor:F. Hoffmann-La Roche AG

Chronic lymphocytic leukaemia+1

Not recruiting

Study Comparing Ibrutinib and Venetoclax with Chlorambucil and Obinutuzumab for First-line Treatment in Patients with Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Bladder transitional cell carcinoma+2

Not recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Alport's syndrome

Not recruiting

Study on the Safety and Effects of Setanaxib for Patients with Alport Syndrome

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Setanaxib
  • Sponsor:Calliditas Therapeutics Suisse S.A.

Dementia of the Alzheimer's type uncomplicated

Not recruiting

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pegipanermin
  • Sponsor:Inmune Bio Inc.

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Novy Hradec Kralove

What the registry says about research in the country

01 Neurological Disorders

Clinical trials focusing on multiple sclerosis and Alzheimer's disease, evaluating novel therapeutic approaches including comparative studies of treatments like frexalimab and investigations of cognitive performance in early-stage Alzheimer's patients with inflammation markers.

  • Relapsing Multiple Sclerosis
  • Early Alzheimer's Disease
  • Neuroinflammatory Conditions

Studies aim to assess treatment efficacy and disease progression markers.

02 Hematologic Malignancies

Comprehensive research into blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and various lymphomas, testing innovative combination therapies and treatment approaches.

  • Leukemia Treatment Protocols
  • Lymphoma Management
  • Novel Drug Combinations

Focus on improving survival rates and treatment outcomes for blood cancer patients.

03 Respiratory Conditions

Studies examining treatments for chronic rhinosinusitis and uncontrolled asthma, with trials evaluating new medications like brensocatib and AZD8630 for symptom management and disease control.

  • Nasal Symptoms Management
  • Asthma Exacerbation Prevention
  • Respiratory Disease Control

Research focused on improving quality of life for patients with chronic respiratory conditions.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.